Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07ZTO
|
||||
| Former ID |
DAP000263
|
||||
| Drug Name |
Bethanechol
|
||||
| Synonyms |
Amidopropyldimethylbetaine; Bethanecol; Urabeth; Myotonine chloride; Duvoid (TN); Myotonachol (TN); Urecholine (TN); Carbamoyl-beta-methylcholine; Carbamyl-beta-methylcholine; Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester); (2-Hydroxypropyl)trimethylammonium carbamate; 1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-(9CI); 2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium; 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium; 2-carbamoyloxypropyl(trimethyl)azanium; 2-carbamoyloxypropyl-trimethylazanium
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Urinary retention [ICD9: 788.2; ICD10:R33] | Approved | [1], [2] | ||
| Therapeutic Class |
Parasympathomimetics
|
||||
| Company |
Merck & Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C7H17N2O2+
|
||||
| InChI |
InChI=1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1
|
||||
| InChIKey |
NZUPCNDJBJXXRF-UHFFFAOYSA-O
|
||||
| CAS Number |
CAS 674-38-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9068, 4422030, 4918193, 8151589, 11335354, 11360593, 11362918, 11365480, 11368042, 11371502, 11373829, 11376204, 11461565, 11467101, 11468221, 11483940, 11486729, 11487948, 11490127, 11492070, 11493898, 26756574, 29221538, 46507707, 47810623, 47810624, 48034978, 48110329, 48184868, 48259086, 48259087, 48259088, 49698975, 49868462, 50105244, 57321286, 77420552, 90341349, 92308844, 92729933, 103544258, 104300395, 124749610, 124879658, 124879659, 124879661, 124879662, 128778196, 131269063, 134337577
|
||||
| SuperDrug ATC ID |
N07AB02
|
||||
| SuperDrug CAS ID |
cas=000674384
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M5 | Target Info | Agonist | [3], [4], [5] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040518. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 297). | ||||
| REF 3 | Postoperative analgesia induced by intrathecal neostigmine or bethanechol in rats. Clin Exp Pharmacol Physiol. 2009 Jul;36(7):648-54. Epub 2008 Nov 28. | ||||
| REF 4 | Morphine increases acetylcholine release in the trigeminal nuclear complex. Sleep. 2008 Dec 1;31(12):1629-37. | ||||
| REF 5 | Loss of Ca-mediated ion transport during colitis correlates with reduced ion transport responses to a Ca-activated K channel opener. Br J Pharmacol. 2009 Apr;156(7):1085-97. Epub 2009 Mar 9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.